CA2864031C - Hydrocortisone controlled release formulation - Google Patents

Hydrocortisone controlled release formulation Download PDF

Info

Publication number
CA2864031C
CA2864031C CA2864031A CA2864031A CA2864031C CA 2864031 C CA2864031 C CA 2864031C CA 2864031 A CA2864031 A CA 2864031A CA 2864031 A CA2864031 A CA 2864031A CA 2864031 C CA2864031 C CA 2864031C
Authority
CA
Canada
Prior art keywords
composition
hydrocortisone
depression
composition according
delayed release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2864031A
Other languages
English (en)
French (fr)
Other versions
CA2864031A1 (en
Inventor
Hiep Huatan
Richard Ross
Martin Whitaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine UK Ltd
Original Assignee
Diurnal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diurnal Ltd filed Critical Diurnal Ltd
Publication of CA2864031A1 publication Critical patent/CA2864031A1/en
Application granted granted Critical
Publication of CA2864031C publication Critical patent/CA2864031C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2864031A 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation Active CA2864031C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1202433.7A GB201202433D0 (en) 2012-02-13 2012-02-13 Controlled drug release
GB1202433.7 2012-02-13
US201261599704P 2012-02-16 2012-02-16
US61/599,704 2012-02-16
US201261600958P 2012-02-20 2012-02-20
US61/600,958 2012-02-20
PCT/GB2013/050311 WO2013121184A1 (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation

Publications (2)

Publication Number Publication Date
CA2864031A1 CA2864031A1 (en) 2013-08-22
CA2864031C true CA2864031C (en) 2019-11-12

Family

ID=45930017

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2864031A Active CA2864031C (en) 2012-02-13 2013-02-12 Hydrocortisone controlled release formulation

Country Status (29)

Country Link
US (2) US9750704B2 (enEXAMPLES)
EP (1) EP2814469B1 (enEXAMPLES)
JP (1) JP6293678B2 (enEXAMPLES)
KR (1) KR102023559B1 (enEXAMPLES)
CN (2) CN104105481A (enEXAMPLES)
AU (1) AU2013220139B2 (enEXAMPLES)
BR (1) BR112014020008B1 (enEXAMPLES)
CA (1) CA2864031C (enEXAMPLES)
CY (1) CY1123202T1 (enEXAMPLES)
DK (1) DK2814469T3 (enEXAMPLES)
ES (1) ES2792069T3 (enEXAMPLES)
GB (2) GB201202433D0 (enEXAMPLES)
HK (1) HK1203824A1 (enEXAMPLES)
HR (1) HRP20200780T1 (enEXAMPLES)
HU (1) HUE048904T2 (enEXAMPLES)
IL (2) IL234061B (enEXAMPLES)
IN (1) IN2014DN06808A (enEXAMPLES)
LT (1) LT2814469T (enEXAMPLES)
ME (1) ME03742B (enEXAMPLES)
MX (1) MX361407B (enEXAMPLES)
NZ (2) NZ715616A (enEXAMPLES)
PL (1) PL2814469T3 (enEXAMPLES)
PT (1) PT2814469T (enEXAMPLES)
RS (1) RS60346B1 (enEXAMPLES)
RU (1) RU2619869C2 (enEXAMPLES)
SI (1) SI2814469T1 (enEXAMPLES)
SM (1) SMT202000286T1 (enEXAMPLES)
WO (1) WO2013121184A1 (enEXAMPLES)
ZA (1) ZA201508728B (enEXAMPLES)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
US20160367755A1 (en) * 2015-06-01 2016-12-22 Massachusetts Institute Of Technology System and method for neuroendocrine control
FR3057775B1 (fr) * 2016-10-26 2018-11-02 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
KR101982287B1 (ko) * 2019-01-04 2019-05-24 (주)청아굿푸드 천연 추출물 함유 서방성 제제 및 그 제조방법
AU2022209123A1 (en) 2021-01-15 2023-07-06 Galventa Ag Pulsatile release caffeine formulation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6013711A (ja) * 1983-06-21 1985-01-24 ザ、プロクタ−、エンド、ギヤンブル、カンパニ− コルチコステロイドを含有する浸透局所製薬組成物
US4552872A (en) 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
GB2292079B (en) * 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
DK0876142T3 (da) 1996-01-16 2001-11-19 Advanced Polymer Systems Inc Topisk tilførsel af lægemidler til den nedre mavetarmkanal
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
WO2002017887A1 (de) * 2000-08-29 2002-03-07 Mepha Ag Arzneimittel zur behandlung von darmerkrankungen
IL157634A0 (en) * 2001-03-13 2004-03-28 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms containing glucocorticosteroid
KR20040025741A (ko) * 2001-08-06 2004-03-25 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
NZ532564A (en) 2001-11-23 2006-06-30 Procter & Gamble Solid unit dosage forms for oral administration which minimise the impact of coating fractures especially for larger or heavier dosage forms
DE602004028497D1 (de) 2003-09-15 2010-09-16 Nycomed Gmbh Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
GB0400031D0 (en) * 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
JP2009545546A (ja) * 2006-08-03 2009-12-24 ニテック ファーマ アクチエンゲゼルシャフト リウマチ性疾患の遅延放出型グルココルチコイド治療
CA2678131A1 (en) 2006-11-17 2008-05-22 Antoine Andremont Colonic delivery using zn/pectin beads with a eudragit coating.
WO2008117814A1 (ja) 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. 大腸送達用経口製剤
KR20100121601A (ko) * 2007-12-17 2010-11-18 콤비네이토릭스, 인코포레이티드 면역염증성 질환의 치료를 위한 치료요법
GB0817120D0 (en) * 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
WO2010113177A2 (en) * 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Oral insulin delivery systems for controlling diabetes
SG174583A1 (en) * 2009-04-07 2011-10-28 Duocort Pharma Ab Improved glucocorticoid therapy
KR20120110098A (ko) 2009-11-16 2012-10-09 에보니크 룀 게엠베하 고형 (메트)아크릴레이트 공중합체를 분산제에 의해 분산된 형태로 전환시키는 방법
IT1405012B1 (it) * 2010-08-06 2013-12-16 Sofar Spa Composizioni di beclometasone dipropionato in microsfere gastroresistenti a rilascio modificato e processo per il loro ottenimento
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release

Also Published As

Publication number Publication date
AU2013220139B2 (en) 2017-08-31
IL234061B (en) 2018-03-29
KR102023559B1 (ko) 2019-09-23
GB2502402A (en) 2013-11-27
US20140370113A1 (en) 2014-12-18
NZ627468A (en) 2016-02-26
GB201202433D0 (en) 2012-03-28
US9750704B2 (en) 2017-09-05
SI2814469T1 (sl) 2020-07-31
EP2814469B1 (en) 2020-04-08
EP2814469A1 (en) 2014-12-24
BR112014020008B1 (pt) 2022-05-24
US20170296475A1 (en) 2017-10-19
CN104105481A (zh) 2014-10-15
CY1123202T1 (el) 2021-10-29
KR20140121478A (ko) 2014-10-15
IL245546A0 (en) 2016-06-30
CN110141557A (zh) 2019-08-20
PT2814469T (pt) 2020-05-22
MX361407B (es) 2018-12-04
HK1203824A1 (en) 2015-11-06
PL2814469T3 (pl) 2020-07-13
AU2013220139A1 (en) 2014-08-07
BR112014020008A8 (pt) 2018-01-23
IN2014DN06808A (enEXAMPLES) 2015-05-22
LT2814469T (lt) 2020-05-25
IL234061A0 (en) 2014-09-30
HUE048904T2 (hu) 2020-08-28
RS60346B1 (sr) 2020-07-31
HRP20200780T1 (hr) 2020-10-02
ME03742B (me) 2021-04-20
NZ715616A (en) 2017-03-31
JP2015506972A (ja) 2015-03-05
SMT202000286T1 (it) 2020-07-08
CA2864031A1 (en) 2013-08-22
ES2792069T3 (es) 2020-11-06
RU2014130866A (ru) 2016-04-10
RU2619869C2 (ru) 2017-05-18
JP6293678B2 (ja) 2018-03-14
US10166194B2 (en) 2019-01-01
ZA201508728B (en) 2017-09-27
MX2014009716A (es) 2015-01-14
WO2013121184A1 (en) 2013-08-22
GB2502402B (en) 2014-11-12
DK2814469T3 (da) 2020-05-04
GB201302406D0 (en) 2013-03-27

Similar Documents

Publication Publication Date Title
US10166194B2 (en) Hydrocortisone controlled release formulation
CN1404389B (zh) 时控脉冲给药系统
AU2020227021B2 (en) Methods and compositions particularly for treatment of attention deficit disorder
RU2504362C2 (ru) Системы доставки лекарственных веществ, включающие в себя слабоосновные лекарственные вещества и органические кислоты
US20130059010A1 (en) Alcohol-resistant oral pharmaceutical form
AU2007267159B2 (en) Lipoic acid pellets
JP2024506595A (ja) センタナファジン製剤ならびにその製造および使用方法
JP2005521682A (ja) 結腸放出組成物
CN117157079A (zh) 一种口服肠溶皮质类固醇的药物组合物
AU782030B2 (en) Multiparticulate formulations of lithium salts for oral administration suitable for-a-day administration
ZA200505180B (en) Process for manufacturing sustained release microbeads containing venlafaxine HCI
US20150086626A1 (en) Stable dosage forms of skeletal muscle relaxants with extended release coating
GB2510754A (en) Delayed release hydrocortisone composition
CN114425046B (zh) 一种盐酸地尔硫卓缓释胶囊
CN1985810A (zh) 盐酸哌甲酯缓控释胶囊及其制备方法
CN105326813A (zh) 帕罗西汀缓释组合物及其制备方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180111